Stocks Health care INDV
NASDAQ · Health careIndivior Pharmaceuticals, Inc. (INDV)
Indivior Pharmaceuticals, Inc. brought in $1.3B of revenue over the twelve months to June 30, 2026. Net income was $356M, a net margin of 26.7%. In fiscal 2025 capital spending exceeded operating cash flow by $93M. At June 30, 2026 it held $222M in cash against $487M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 3, 2026.
What Indivior Pharmaceuticals, Inc. does
Indivior Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker INDV.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.2B | $210M | $1.64 | -$93M |
| 2024 | $1.2B | $7M | $0.05 | $7M |
| 2023 | $1.1B | -$126M | -$0.92 | -$308M |
| 2023 | $901M | -$44M | -$0.32 | -$9M |
| 2021 | $791M | $205M | n/a | $349M |
Latest SEC filings
What Indivior Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 17, 2026Form 425 filing 425
- September 17, 2026
- September 15, 2026
- September 11, 2026
- September 9, 2026
- August 28, 2026
- August 13, 2026Activist stake changed SCHEDULE 13D/A
- August 4, 2026Form 425 filing 425
- August 3, 2026Form 425 filing 425
- August 3, 2026Quarterly report 10-Q · period to June 30, 2026
Questions about INDV
What does Indivior Pharmaceuticals, Inc. do?
Indivior Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker INDV.
Is Indivior Pharmaceuticals, Inc. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $356M on revenue of $1.3B, a net margin of 26.7%.
How much revenue does Indivior Pharmaceuticals, Inc. make?
Over the twelve months to June 30, 2026 Indivior Pharmaceuticals, Inc. reported revenue of $1.3B.
When did Indivior Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 3, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the form 425 filing from September 17, 2026.
Similar companies
Follow INDV
Get an email when Indivior Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow INDV: get an email when it filesWhere the numbers come from
Financial figures are the values Indivior Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.